VEGFA and angiosarcoma: Bevacizumab (Avastin®; Genentech, Inc., South San Francisco, CA, USA) is a monoclonal antibody anti-VEGF, potentially inhibiting tumoral angiogenesis, considered as a promising therapy, but in recent studies was found to not be beneficial for human angiosarcoma treatment [134].